Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 13-cis-isomer Fenretinide
2. 4 Hydroxyphenylretinamide
3. 4-hpr
4. 4-hydroxyphenylretinamide
5. Fenretinide, 13 Cis Isomer
6. Fenretinide, 13-cis-isomer
7. Fenretinimide
8. Mcn R 1967
9. Mcn-r-1967
10. Mcnr1967
11. N-(4-hydroxyphenyl)-trans-retinamide
12. N-(4-hydroxyphenyl)retinamide
1. 65646-68-6
2. N-(4-hydroxyphenyl)retinamide
3. 4-hpr
4. 4-hydroxyphenylretinamide
5. 4-hydroxyphenyl Retinamide
6. Retinoic Acid P-hydroxyanilide
7. All-trans-4'-hydroxyretinanilide
8. Mcn-r-1967
9. Fenretinida
10. Fenretinidum
11. 4-hydroxy(phenyl)retinamide
12. N-(4-hydroxyphenyl)all-trans Retinamide
13. Retinamide, N-(4-hydroxyphenyl)-
14. Rii Retinamide
15. Retinoic Acid P-hydroxyphenylamide
16. 4-(hydroxyphenyl)retinamide
17. 15-[(4-hydroxyphenyl)amino]retinal
18. (2e,4e,6e,8e)-n-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamide
19. Nsc-760419
20. 187ej7qexl
21. Chembl7301
22. Mls002701698
23. Chebi:42588
24. Nsc-374551
25. Ncgc00090752-03
26. Dsstox_cid_12005
27. Dsstox_rid_78900
28. Dsstox_gsid_32005
29. Fenretinidum [latin]
30. Fenretinida [spanish]
31. 4hpr
32. Fenretinide [usan:inn]
33. Smr001456303
34. Cas-65646-68-6
35. Ccris 3260
36. Sr-01000075917
37. (2e,4e,6e,8e)-n-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide
38. Mfcd00792674
39. Unii-187ej7qexl
40. Brn 5769490
41. Syt-101
42. St-602
43. Fenretinide; 4-hpr
44. Fenretinide (4-hpr)
45. P-hydroxyphenylretinamide
46. Fenretinide [mi]
47. Spectrum5_001939
48. Fenretinide [inn]
49. Fenretinide (usan/inn)
50. Fenretinide [usan]
51. Fenretinide [vandf]
52. Fenretinide [mart.]
53. Lopac0_000625
54. Schembl11703
55. Schembl11704
56. Bspbio_001419
57. Fenretinide [who-dd]
58. Mls001055399
59. Mls006010811
60. Bml2-e08
61. N-(4-hydroxyphenyl)-retinamide
62. Dtxsid2032005
63. Schembl15703189
64. Chebi:92493
65. Amy9087
66. 15-(4-hydroxyanilino)retinal #
67. Hms1361g21
68. Hms1791g21
69. Hms1989g21
70. Hms2089b17
71. Hms3261n12
72. Hms3402g21
73. Hms3412m06
74. Hms3676m06
75. Pharmakon1600-01505602
76. 4-hpr;(4-hydroxyphenyl)retinamide
77. Bcp06908
78. Ex-a4102
79. N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenamide
80. Zinc3871023
81. Tox21_111007
82. Tox21_200989
83. Tox21_500625
84. 1-enyl)nona-2,4,6,8-tetraenamide
85. Bdbm50092055
86. Hsci1_000112
87. Nsc374551
88. Nsc760419
89. S5233
90. Calix[4!-bis-crown-6,95
91. Akos024456572
92. Tox21_111007_1
93. Ccg-204713
94. Cs-0789
95. Db05076
96. Lp00625
97. Mk-4016
98. N-(4-hydroxyphenyl)retinamide, 4-hpr
99. Nsc 760419
100. Sdccgsbi-0050606.p002
101. All-trans-n-(4-hydroxyphenyl)retinamide
102. Dimethyl-9-(2,6,6-trimethylcyclohex-
103. Idi1_033889
104. Retinoic Acid P-hydroxyanilide, >=95%
105. Ncgc00090752-01
106. Ncgc00090752-02
107. Ncgc00090752-04
108. Ncgc00090752-05
109. Ncgc00090752-06
110. Ncgc00090752-07
111. Ncgc00090752-09
112. Ncgc00090752-10
113. Ncgc00090752-11
114. Ncgc00090752-12
115. Ncgc00090752-20
116. Ncgc00258542-01
117. Ncgc00261310-01
118. As-59667
119. Bp-13369
120. Hy-15373
121. Smr000677938
122. Eu-0100625
123. H1464
124. D04162
125. H 7779
126. (2e,4e,6e,8e)-n-(4-hydroxyphenyl)-3,7-
127. Ab00172992-07
128. 646f686
129. A835178
130. Q5443576
131. Sr-01000075917-1
132. Sr-01000075917-4
133. N-(4-hydroxyphenyl)-all-trans-vitamin A Amide
134. (2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenoic Acid (4-hydroxy-phenyl)-amide
135. (2e,4e,6e,8e)-n-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenamide
136. (2e,4e,6e,8e)-n-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide
137. (2e,4e,6e,8e)-n-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide;fenretinide
138. 2,6,8-nonatetraenamide, N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl-, (all-e)-
139. 3,7-dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenoic Acid (4-hydroxy-phenyl)-amide
140. N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraeneamide
| Molecular Weight | 391.5 g/mol |
|---|---|
| Molecular Formula | C26H33NO2 |
| XLogP3 | 7.3 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 6 |
| Exact Mass | 391.251129295 g/mol |
| Monoisotopic Mass | 391.251129295 g/mol |
| Topological Polar Surface Area | 49.3 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 726 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 4 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in macular degeneration.
Anticarcinogenic Agents
Agents that reduce the frequency or rate of spontaneous or induced tumors independently of the mechanism involved. (See all compounds classified as Anticarcinogenic Agents.)
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Fenretinide has known human metabolites that include (2S,3S,4S,5R)-6-[4-[[(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoyl]amino]phenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
Fenretinide inhibits the growth of several human cancer cell lines, acting through both retinoid-receptor-dependent and retinoid-receptor-independent mechanisms.1In vivo, fenretinide selectively accumulates in breast tissue and is particularly active in inhibiting rat mammary carcinogenesis.1 An important feature of fenretinide is its ability to inhibit cell growth through the induction of apoptosis rather than through differentiation, an effect that is strikingly different from that of vitamin A.1 In contrast to tamoxifen, which inhibits only estrogen receptor (ER)-positive tumors, fenretinide induces apoptosis in both ER-positive and ER-negative breast cancer cell lines.2 All of these properties render fenretinide an attractive candidate for breast cancer chemoprevention.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Fenretinide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fenretinide, including repackagers and relabelers. The FDA regulates Fenretinide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fenretinide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Fenretinide supplier is an individual or a company that provides Fenretinide active pharmaceutical ingredient (API) or Fenretinide finished formulations upon request. The Fenretinide suppliers may include Fenretinide API manufacturers, exporters, distributors and traders.
click here to find a list of Fenretinide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Fenretinide DMF (Drug Master File) is a document detailing the whole manufacturing process of Fenretinide active pharmaceutical ingredient (API) in detail. Different forms of Fenretinide DMFs exist exist since differing nations have different regulations, such as Fenretinide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Fenretinide DMF submitted to regulatory agencies in the US is known as a USDMF. Fenretinide USDMF includes data on Fenretinide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Fenretinide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Fenretinide suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Fenretinide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Fenretinide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Fenretinide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Fenretinide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Fenretinide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Fenretinide suppliers with NDC on PharmaCompass.
Fenretinide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Fenretinide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Fenretinide GMP manufacturer or Fenretinide GMP API supplier for your needs.
A Fenretinide CoA (Certificate of Analysis) is a formal document that attests to Fenretinide's compliance with Fenretinide specifications and serves as a tool for batch-level quality control.
Fenretinide CoA mostly includes findings from lab analyses of a specific batch. For each Fenretinide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Fenretinide may be tested according to a variety of international standards, such as European Pharmacopoeia (Fenretinide EP), Fenretinide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fenretinide USP).
LOOKING FOR A SUPPLIER?
